Human MLH1 status can potentially predict cisplatin sensitivity but not microsatellite instability in head and neck squamous cell carcinoma cells

Experimental and Therapeutic Medicine

Volumn 1, Issue 1, 2010, Pages 93-96

  Adachi, Makoto ^a   Ijichi, Kei ^b   Hasegawa, Yasuhisa ^c   Nakamura, Hideaki ^d   Ogawa, Tetsuya ^e   Kanematsu, Nobutake ^f  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

^d NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^e AICHI MEDICAL UNIVERSITY   (Japan)

^f ASAHI UNIVERSITY   (Japan)

Author keywords

Cisplatin; Head and neck cancer; Hmlh1; Microsatellite instability; Mismatch repair system

Indexed keywords

CISPLATIN; MESSENGER RNA; PROTEIN MLH1; PROTEIN MSH2;

ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CONTROLLED STUDY; DRUG SENSITIVITY; HEAD AND NECK CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA CELL; HUMAN; HUMAN CELL; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; PHENOTYPE; PREDICTION; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

EID: 77955766083     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm_00000017     Document Type: Article

References (16)

1. Choong N and Vokes E: Expanding role of the medical oncologist in the management of head and neck cancer. CA Cancer J Clin 58: 32-53, 2008.
2. Wozniak K and Blasiak J: Recognition and repair of DNA -cisplatin adducts. Acta Biochim Pol 49: 583-596, 2002.
3. Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265-7279, 2003.
4. Yang Z, Faustino PJ, Andrews PA, Monastra R, Rasmussen AA, Ellison CD and Cullen KJ: Decreased cisplatin/DNA adduct formation is associated with cisplatin resistance in human head and neck cancer cell lines. Cancer Chemother Pharmacol 46: 255-262, 2000.
5. Papouli E, Cejka P and Jiricny J: Dependence of the cytotoxicity of DNA -damaging agents on the mismatch repair status of human cells. Cancer Res 64: 3391-3394, 2004.
6. Colella G, Marchini S, D'Incalci M, Brown R and Broggini M: Mismatch repair deficiency is associated with resistance to DNA minor groove alkylating agents. Br J Cancer 80: 338-343, 1999.
7. Geisler JP, Goodheart MJ, Sood AK, Holmes RJ, Hatterman-Zogg MA and Buller RE: Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma. Cancer 98: 2199-2206, 2003.
8. Ishizaki K, Nishizawa K, Kato T, Kitao H, Han ZB, Hirayama J J, Suzuki F, Cannon TF, Kamigaichi S, Tawarayama Y, Masukawa M M, Shimazu T and Ikenaga M: Genetic changes induced in human cells in Space Shuttle experiment (STS-95). Aviat Space Environ Med 72: 794-798, 2001.
9. Manic S, Gatti L, Carenini N, Fumagalli G, Zunino F and Perego P: Mechanisms controlling sensitivity to platinum complexes: role of p53 and DNA mismatch repair. Curr Cancer Drug Targets 3: 21-29, 2003.
10. Pani E, Stojic L, El-Shemerly M, Jiricny J and Ferrari S: Mismatch repair status and the response of human cells to cisplatin. Cell Cycle 15: 1796-1802, 2007.
11. Shimodaira H, Yoshioka-Yamashita A, Kolodner RD and Wang JY: Interaction of mismatch repair protein PM S2 and the p53-related transcription factor p73 in apoptosis response to cisplatin. Proc Natl Acad Sci USA 100: 2420-2425, 2003.
12. Cejka P, Stojic L, Mojas N, Russell AM, Heinimann K, Cannavó E, di Pietro M, Marra G and Jiricny J: Methylation-induced G(2)/M arrest requires a full complement of the mismatch repair protein hMLH 1. EM BO J 22: 2245-2254, 2003.
13. Stojic L, Brun R and Jiricny J: Mismatch repair and DNA damage signaling. DNA Repair 3: 1091-1101, 2004.
14. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, Tu D, Redston M and Gallinger S: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349: 247-257, 2003.
15. Helleman J, van Staveren fnameIL/fname, Dinjens WN, van Kuijk PF, Ritstier K, Ewing PC, van der Burg ME, Stoter G and Berns EM: Mismatch repair and treatment resistance in ovarian cancer. BMC Cancer 31: 201, 2006.
16. Magnowska M, Surowiak P, Nowak-Markwitz E, Michalak M, Magnowski P, Rokita W, Kedzia H, Zabel M and Spaczyński M: Analysis of hMLH 1 and hMSH2 expression in cisplatin-treated ovarian cancer patients. Ginekol Pol 79: 826-834, 2008.